2022 Fiscal Year Final Research Report
Osteogenesis Promotion Using Drug Repositioning
| Project/Area Number |
18K17105
|
|---|
| Research Category |
Grant-in-Aid for Early-Career Scientists
|
| Allocation Type | Multi-year Fund |
|---|
| Review Section |
Basic Section 57040:Regenerative dentistry and dental engineering-related
|
|---|
| Research Institution | Aichi Gakuin University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2018-04-01 – 2023-03-31
|
| Keywords | Geranylgeranylacetone |
|---|
| Outline of Final Research Achievements |
We focused on geranylgeranylacetone (GGA), which is known as a heat shock proteins (HSPs) inducing agent. GGA is mainly used as a gastric mucosal protective agent; however, its effects on bone tissues have not been studied. Therefore, we hypothesized that “GGA induces HSPs in osteoblasts thereby promotes cell differentiation”, and administered GGA to MC3T3E-1 cells to examine cell responses. As a results, GGA promoted the differentiation of MC3T3E-1 in an in vitro cell culture model.
|
| Free Research Field |
骨再生医療
|
| Academic Significance and Societal Importance of the Research Achievements |
医薬品を新たに開発するのではなく、開発が中断した薬剤や市販の薬剤を新規効能として利用するドラッグリポジショニングを用いて研究を行うことにした。今回注目した薬剤はGGAが主成分でありHSP誘導能をもつテプレノンである。しかしながら今までに骨の治癒を促進する生物学的な機序を明らかにした報告はない。したがって本研究では我々が確立した実験方法に準じて骨芽細胞様細胞に対してGGAを投与した結果コラーゲン生成量が増加し石灰化促進することを確認することができた。
|
